The Lancet Gastroenterology & Hepatology
Fecha de publicación: July 2020
Autores: Nick Powell, PhD., Hajir Ibraheim, MBBS., Tim Raine, PhD., Richard A Speight, MBBS., Sophie Papa, PhD., Oliver Brain, DPhil., et al.
Background: Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction.Leer más